Target volume definition for staple line recurrences of non-small cell lung cancer
Abstract
Background: Staple line (SL) recurrences of non-small cell lung cancer (NSCLC) are commonly treated with radiotherapy (RT), but the target volume definition — whole SL versus focused on recurrence — is unclear.
The aim of the study was to determine the appropriate target volume for RT of SL recurrences.
Materials and methods: Twenty-two consecutive patients (20 stage I, 2 stage II) treated with salvage RT for SL recurrences were retrospectively analyzed. Imaging features at the time of SL recurrence were evaluated to guide target volume definition.
Results:
Surgery: All patients had complete tumor resection (wedge resection in 10 (45%) and lobectomy in 12 (55%) patients). 14 (64%) patients had risk factors for recurrence, including surgical margins ≤ 2 cm, angiolymphatic and visceral pleural invasion.
Salvage RT: After a median 26 months (9–67), all 22 patients developed SL recurrence which was metabolically active on PET in all and biopsy-confirmed in 18/22 (82%) patients. All patients underwent RT targeting the location of the SL recurrence only. 13/22 (59%) patients had additional PET-negative nodular or linear SL changes that were not included in the irradiated volume.
Recurrence after RT: After a median 17 months (9–34) 10/22 (45%) patients recurred either regionally 6/10 (60%), in the lungs 4/10 (40%) or distally 3/10 (30%). No patient recurred at the SL. Two-year overall and disease-free survival rates after RT were 71% and 65%, respectively.
Conclusion: RT to SL recurrences alone results in excellent local control. Additional treatment to reduce regional and distant recurrences should be considered.
Keywords: radiotherapystaple linenon-small cell lung cancerSABRrecurrence
References
- Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e278S–e313S.
- Billè A, Ahmad U, Woo KM, et al. Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up. Ann Thorac Surg. 2016; 102(4): 1067–1073.
- Fedor D, Johnson WR, Singhal S. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg Oncol. 2013; 22(3): 156–161.
- Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60(3): 615–22; discussion 622.
- Sittenfeld SMC, Juloori A, Reddy CA, et al. Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer. Clin Lung Cancer. 2021; 22(3): e360–e365.
- Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg. 2014; 147(2): 747–52: Discussion 752.
- Varlotto JM, Yao AN, DeCamp MM, et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. Int J Radiat Oncol Biol Phys. 2015; 91(4): 765–773.
- Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009; 115(22): 5218–5227.
- Razi SS, Daskalaki D, Burack J. Current trends in lung resection for T1a non-small cell lung cancer: is lobectomy still the answer? J Thorac Dis. 2017; 9(2): E164–E165.
- Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer. 2011; 71(2): 156–165.
- Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012; 93(6): 1813–20; discussion 1820.
- Hung JJ, Yeh YC, Hsu WH, et al. Prognostic Factors of Survival after Recurrence in Patients with Resected Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(9): 1328–1336.
- Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J. 2006; 12(4): 283–288.
- Aoki S, Yamashita H, Takahashi W, et al. Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients. Oncol Lett. 2020; 19(4): 2695–2704.
- Sun B, Brooks ED, Komaki R, et al. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017; 12(6): 983–992.
- Agolli L, Valeriani M, Carnevale A, et al. Role of salvage stereotactic body radiation therapy in post-surgical loco-regional recurrence in a selected population of non-small cell lung cancer patients. Anticancer Res. 2015; 35(3): 1783–9.
- Emami B, Graham MV, Deedy M, et al. Radiation therapy for intrathoracic recurrence of non-small cell lung cancer. Am J Clin Oncol. 1997; 20(1): 46–50.
- Jeremic B, Shibamoto Y, Milicic B, et al. External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection. Lung Cancer. 1999; 23(2): 135–142.
- Sun B, Kamel MK, Nasar A, et al. Staple Line Thickening After Sublobar Resection: Reaction or Recurrence? Ann Thorac Surg. 2020; 109(6): 1670–1676.
- Milano MT, Kong FMS, Movsas B. Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. Transl Lung Cancer Res. 2019; 8(1): 78–87.
- Hou Y, Hermann G, Lewis JH, et al. Clinical Outcomes After Lung Stereotactic Body Radiation Therapy in Patients With or Without a Prior Lung Resection. Am J Clin Oncol. 2018; 41(7): 695–701.
- Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11): 1070–1076.
- Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2019; 103(5): 1077–1084.
- Zhao L, Zhou S, Balter P, et al. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 95(4): 1226–1235.
- Takeda A, Sanuki N, Eriguchi T, et al. Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer. Ann Thorac Surg. 2013; 96(5): 1776–1782.
- Xiong W, Xu Q, Xu Y, et al. Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects. BMC Cancer. 2014; 14: 719.
- Giuliani ME, Hope A, Mangona V, et al. Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group. Clin Lung Cancer. 2017; 18(2): 162–168.
- Videtic GMM, Hu C, Singh AK, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015; 93(4): 757–764.
- Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12): 1394–1403.